English
Regional settings| Spread | 0.14 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 103.72 |
| Open | 103.49 |
| 1-Year Change | 28.11% |
| Day's Range | 103.02 - 103.72 |
Cardinal Health, Inc. is a healthcare services and products company. The Company operates through two segments: Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare and consumer products. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals; and repackages generic pharmaceuticals and over-the-counter healthcare products. The Medical segment manufactures, sources and distributes a range of medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. This segment also distributes a range of national brand products and provides supply chain services and solutions to hospitals and other healthcare providers.
BRIEF: For the six months ended 31 December 2021, Cardinal Health Inc revenues increased 11% to $89.43B. Net income decreased 15% to $320M. Revenues reflect Pharmaceutical segment increase of 12% to $81.2B, United States segment increase of 11% to $87.22B. Net income was offset by Medical segment income decrease of 63% to $173M, Corporate segment loss increase of 7% to $1.54B. Dividend per share increased from $0.97 to $1.47.
Common no Par, 3/11, 755M auth., 363,600,000 issd., less 13,300,000 in Treas. @ $487.2M. Insiders & Strategic holders own 0.10%. IPO:9/94, 7M shs @ $39 by Smith Barney. *FY'97 -'99 fncls & '98-'99 Q rest'd for merger with Scherer(8/98),llegiance (3/99), PSI(5/99), & ALP (9/99).
